<a href="https://www.fiercebiotech.com/biotech/roche-bets-700m-upfront-nurixs-late-phase-btk-degrader-set-lilly-showdown" hreflang="en">Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown</a>
Roche has invested $700 million upfront and up to $2.3 billion in milestones to co-develop Nurix Therapeutics' BTK degrader, bexobrutideg, which is set to compete against Eli Lilly’s Jaypirca in a phase 3 trial for blood cancer treatment. This collaboration aims to leverage Roche's resources to enhance the development of bexobrutideg, which Nurix believes may offer improved patient outcomes compared to existing BTK inhibitors.
Roche's $700 million upfront investment in Nurix's BTK degrader highlights the strategic shift towards protein degradation over traditional inhibition in treating blood cancers like CLL and SLL. This move not only positions Roche and Nurix to potentially outperform Eli Lilly's Jaypirca but also underscores the growing importance of collaborative partnerships in expanding the therapeutic and commercial reach of novel biotech solutions. For a professional in healthtech and biotech, this signals a compelling investment and collaboration opportunity in protein degradation technologies, particularly in oncology.